Product Data Sheet

LY2835219

Cat. No.:	A1794
CAS No.:	1231930-82-7
Formula:	C27H32F2N8·CH4O3S
M.Wt:	602.7
Synonyms:	
Target:	Cell Cycle/Checkpoint
Pathway:	Cyclin-Dependent Kinases
Storage:	Store at -20°C



Solvent & Solubility

In Vitro

≥30.15mg/mL in DMSO

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1mg	5mg	10mg
1 mM	1.6592 mL	8.2960 mL	16.5920 mL
5 mM	0.3318 mL	1.6592 mL	3.3184 mL
10 mM	0.1659 mL	0.8296 mL	1.6592 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	CDK4/6 inhibitor,potent and selective
IC_{50} & Target	2 nM (CDK4), 10 nM (CDK6)

In Vitro

Cell Viability Assay

Cell Line:	Colo-205 colorectal cells, MDA-MB-361 and MCF10A breast cancer cell lines, MV4-11 AML cells.
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	24 h

	Applications:	LY2835219 is a selective and orally available dual cyclin-dependent kinases 4/6 (CDK4/6) inhibitor. LY2835219 (6000 nM) inhibits Rb phosphorylation with IC50 value of 120 nM and a corresponding arrest of cells in G1 (2 N DNA content) with EC50 value of 72 nM.
In Vivo	**Animal experiment**	
	Animal models:	Mice bearing colo-205 xenograft tumors.
	Dosage form:	12.5 mg/kg, 25 to 100mg/kg
	Applications:	LY2835219 mediates CDK4/6 inhibition, cell-cycle arrest and tumor growth inhibition (TGI) in colo-205 and inhibits Rb phosphorylation by CDK4/6. LY2835219 significantly inhibits tumor growth, doses up to 100 mg/kg are well tolerated with no loss of body weight or other signs of toxicity during or after treatment.
	Preparation method:	Formulated in 1 % hydroxyethyl cellulose + 0.1 % antifoam in 25 mM PB pH 2 and administered orally by gavage (final volume 0.2 mL).
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs, 2014, 32(5): 825-837.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com